Transforming Healthcare Ecosystems with Artificial Intelligence
Two sessions over two days devoted entirely to AI
Artificial Intelligence (AI) is the new buzzword in biomedicine, and for good reason. With the potential to drastically reduce the time and cost burdens of drug development, the biggest names in Big Pharma are already utilizing this powerful tool. AI is increasingly important in today’s ‘smart’ healthcare settings; assisting in hospital admission triage and patient management, ‘viewing’ and analyze medial images to detect breast and other cancers, and identifying disease biomarkers for conditions such as Alzheimer’s. A vital tool in the pandemic era, AI has proven its worth in time-critical case tracking assignments and other epidemiological tasks.
A reflection of its importance, BIO Asia–Taiwan 2020 has dedicated two sessions over two days entirely to AI, with a twelve international speakers presenting the latest advances, case studies and future application scenarios for this exciting new technology.
Don’t miss Leo Anthony Celi, Principal Research Scientist, Massachusetts Institute of Technology, with his presentation ‘Battling the Pandemic with Open Science and Cross-Disciplinary Collaboration’; Faisal Khan of AstraZeneca with his talk ‘How to Apply AI to Different Stages of Drug Development’; and Joris Van Dam and Stephane Wolf of Novartis with his presentation ‘Why and How Pharma Use AI in Digital Therapeutics Platform’. Catch these and more AI-focused presentations and panel discussions at Sessions 7 and 14, BIO Asia–Taiwan 2020.
©www.geneonline.com All rights reserved. Collaborate with us: email@example.com